Table 1 Baseline characteristics
| Â | N = 12 |
|---|---|
Age, years | 66 ± 9 |
Men, n (%) | 9 (75) |
Diabetes mellitus, n (%) | 7 (58) |
Hyperlipidaemia, n (%) | 12 (100) |
Hypertension, n (%) | 10 (83) |
Current cigarette smoker, n (%) | 6 (50) |
Percutaneous coronary intervention, n (%) | 10 (83) |
Coronary artery bypass surgery, n (%) | 7 (58) |
Injected treatment site, n (%): | Â |
   Inferior wall | 7 (32) |
   Lateral wall | 2 (9) |
   Anterior wall | 5 (23) |
   Septal wall | 8 (36) |
Medication at baseline, n (%) | Â |
   Angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers | 6 (50) |
   Aspirin and/or clopidogrel | 16 (100) |
   β- blockers | 12 (100) |
   Calcium channel blockers | 8 (67) |
   Nitrates | 12 (100) |
   Statins | 16 (100) |
Medication at 6 months, n (%) | Â |
   Angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers | 6 (50) |
   Aspirin and/or clopidogrel | 16 (100) |
   β- blockers | 12 (100) |
   Calcium channel blockers | 7 (58) |
   Nitrates | 11 (92) |
   Statins | 16 (100) |